Correction to “Efficacy and safety of teclistamab in triple‐class exposed relapsed/refractory multiple myeloma: Pooled findings from three clinical cohorts and a retrospective cohort”

Documenti analoghi

• Efficacy and safety of teclistamab in triple‐class exposed relapsed/refractory multiple myeloma: Pooled findings from three clinical cohorts and a retrospective cohort
  di: Thomas G. Martin, et al.
  Pubblicazione: (2026)
• A real‐world retrospective–prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience
  di: Anna Furlan, et al.
  Pubblicazione: (2024)
• Clinical outcomes of pomalidomide‐based and daratumumab‐based therapies in patients with relapsed/refractory multiple myeloma: A real‐world cohort study in China
  di: Xiaoyan Han, et al.
  Pubblicazione: (2024)
• Infections associated with CAR ‐T cell therapy in patients with relapsed refractory multiple myeloma: Risks and prevention strategies
  di: Jing An, et al.
  Pubblicazione: (2024)
• CAR T‐cell therapy shows impressive outcomes for patients with refractory multiple myeloma
  di: Mary Beth Nierengarten
  Pubblicazione: (2025)